Business Description
ABIONYX Pharma is a French biotechnology company focused on developing new drug treatments for kidney, metabolic, and eye diseases, with operations in both France and the United States. Its primary drug candidate, CER-001, is an HDL-mimicking compound currently being tested in late-stage clinical trials for a rare enzyme disorder called LCAT deficiency, as well as in earlier trials for sepsis treatment. The company is also exploring an eye disease application of the same compound, targeting uveitis, which remains in early preclinical testing. Founded in 2005 and based in Balma, France, the company operates both a drug development arm and a contract research services business.
